- Home
- PRTA vs LAB Comparison
PRTA vs LAB Comparison
Compare PRTA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRTA | LAB |
|---|---|---|
| Founded | 2012 | 1999 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.3M | 488.4M |
| IPO Year | 2013 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PRTA | LAB |
|---|---|---|
| Price | $9.53 | $0.99 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 2 |
| Target Price | ★ $19.00 | $1.35 |
| AVG Volume (30 Days) | 387.4K | ★ 2.0M |
| Earning Date | 05-20-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.68 |
| EPS | N/A | ★ N/A |
| Revenue | $814,000.00 | ★ $101,937,000.00 |
| Revenue This Year | $1,395.77 | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $0.92 |
| 52 Week High | $15.14 | $1.72 |
Technical Indicators
Market Signals| Indicator | PRTA | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 26.69 |
| Support Level | $8.23 | $0.97 |
| Resistance Level | $9.59 | $1.41 |
| Average True Range (ATR) | 0.56 | 0.07 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 71.21 | 4.14 |
Price Performance
Historical ComparisonAbout PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.